Disease-related complications in patients with metastatic hormone-sensitive prostate cancer

Chi‐Fai Ng, Christy Wh Mak, S. Y. S. Chan, Li Ml, Ch Leung, Jeremy Yuen‐Chun Teoh, Peter Kf Chiu, Peggy Sk ChuHong 2023 · DOI

Abstract

Among patients with metastatic hormone-sensitive prostate cancer (mHSPC), 70% experienced disease-related complications and unplanned hospital admissions, which substantially burdened both patients and the healthcare system.

Introduction: The Screening Debate and "Reverse Stage Migration"

For years, the medical community has debated the utility of prostate-specific antigen (PSA) screening. While screening can detect cancer early, it often leads to "overdiagnosis" and "overtreatment" of low-risk tumors. Consequently, many clinical guidelines moved away from routine screening.

However, this shift has potentially triggered a "reverse stage migration," where more patients present with advanced, metastatic disease at their initial diagnosis. This study addresses the lack of detailed data on the real-world complications and hospital burdens faced by patients with mHSPC, providing a clearer picture of the clinical costs associated with late-stage presentation.

Methods

Researchers conducted a prospective observational study as part of the Asian Prostate Cancer (A-CaP) Study, utilizing the Hong Kong Prostate Cancer (HK-CaP) database. The cohort consisted of 100 consecutive patients newly diagnosed with mHSPC across five hospitals in Hong Kong between January 2016 and August 2017. Patients were followed for a mean of 32.9 months. Analysis focused on skeletal-related events (SREs), urinary tract complications, and systemic issues such as anemia.

Results: The High Price of Late Diagnosis

The clinical profile of the cohort reflected advanced disease at presentation. The median PSA at diagnosis was a staggering 202.5 ng/mL (for context, a level over 4 ng/mL often triggers concern).

Multi-Faceted Morbidity

Complications were widespread, affecting 70% of the patient population:

  • Skeletal Issues: 41% reported bone pain, 21% developed pathologic fractures, and 8% suffered from spinal cord compression.
  • Urinary Issues: 28% experienced urinary retention (39% of whom required long-term catheters), and 15% developed ureteral obstructions.
  • Systemic Issues: 41% developed anemia, with over half requiring blood transfusions.

The Burden of Unplanned Hospital Admissions

A significant finding was the strain on healthcare infrastructure: 59% of patients had at least one unplanned hospital admission. These were not scheduled treatments but emergency interventions for acute issues.

Figure 1: Causes of unplanned hospital admissions in mHSPC patients.

As shown in the distribution of admission causes, respiratory issues like pneumonia/COPD (14%) and direct cancer complications like bone pain (12%) and anemia (11%) were primary drivers of emergency care.

Survival Outcomes

The median overall survival for the cohort was 3.7 years. Notably, 67.3% of deaths were directly attributed to prostate cancer, highlighting the lethal nature of the disease when diagnosed at the metastatic stage.

Figure 2: Kaplan-Meier curves for overall survival and cancer-specific survival.

Discussion

The high morbidity and frequent emergency admissions observed in this study suggest a need to re-evaluate current screening paradigms. While avoiding overtreatment is a valid goal, the significant burden of advanced disease indicates that a "middle ground" is necessary. The authors suggest that combining PSA screening with advanced diagnostic tools—such as multiparametric MRI or the Prostate Health Index—could help identify high-risk patients early while still protecting those with low-risk disease.

Limitations

The study's findings should be considered alongside certain limitations. The cohort was recruited before the widespread adoption of newer upfront therapies (e.g., abiraterone), which might now mitigate some complications. Additionally, the limited use of bone-protecting agents due to local economic factors may have inflated the rate of skeletal events. Finally, while the prospective design is a strength, the sample size of 100 patients is relatively small, and formal quality-of-life metrics were not collected.

Summary updated

Abstract

Among patients with mHSPC, 70% experienced disease-related complications and unplanned hospital admissions, which substantially burdened both patients and the healthcare system.
BibTeX
@inproceedings{ng2023disease,
  author = {Chi‐Fai Ng and Christy WH Mak and S. Y. S. Chan and Li Ml and CH Leung and Jeremy Yuen‐Chun Teoh and Peter KF Chiu and Peggy SK Chu},
  title = {{Disease-related complications in patients with metastatic hormone-sensitive prostate cancer}},
  booktitle = {Hong},
  year = {2023},
  doi = {10.12809/hkmj219523},
}
Figure